Olema Pharmaceuticals Announces Promising Breast Cancer Trial Results
Company Announcements

Olema Pharmaceuticals Announces Promising Breast Cancer Trial Results

Olema Pharmaceuticals (OLMA) has provided an announcement.

Olema Pharmaceuticals has shared promising interim results from a Phase 1b/2 trial combining palazestrant with ribociclib to treat ER+/HER2- metastatic breast cancer, which showed a high clinical benefit rate and good tolerance levels among patients. The study revealed that the combination therapy did not increase toxicity and maintained a favorable safety profile. These findings support further clinical development of the drug duo as a potential first-line treatment, which will be presented at the ESMO Breast Cancer Annual Congress.

For detailed information about OLMA stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyOlema Oncology reports Q3 EPS (60c), consensus (58c)
Jason CarrOLMA Earnings this Week: How Will it Perform?
TheFlyOlema Oncology presents preclinical data on anti-tumor activity for OP-3136
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App